| 國家衛生研究院 |
2021-11-22 |
Cisd2 slows down liver aging and attenuates age-related metabolic dysfunction in male mice
|
Huang, YL;Shen, ZQ;Huang, CH;Lin, CH;Tsai, TF |
| 國立政治大學 |
2003 |
CISG Art. 81-84, UCC 及BGB中有關契約解除(消)法律效果之比較研究
|
楊芳賢 |
| 國立成功大學 |
2014-07-31 |
cisMEP: an integrated repository of genomic epigenetic profiles and cis-regulatory modules in Drosophila
|
Yang, Tzu-Hsien; Wang, Chung-Ching; Hung, Po-Cheng; Wu, Wei-Sheng |
| 國立成功大學 |
2014-12-08 |
cisMEP: an integrated repository of genomic epigenetic profiles and cis-regulatory modules in Drosophila
|
Yang, Tzu-Hsien; Wang, Chung-Ching; Hung, Po-Cheng; Wu, Wei-Sheng |
| 國立臺灣大學 |
1992 |
Cisplatin and 5-FU in the Treatment of Nasopharyngeal Carcinoma with Distant Metastasis or Recurrence
|
Ko, J. Y.; 張燕良; 徐茂銘; Ko, J. Y.; Chang, Yen-Liang; Hsu, Mow-Ming |
| 中國醫藥大學 |
2011-05 |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia
|
林柏翰(Po-Han Lin); 邱昌芳(Chang-Fang Chiu); (Lu, YS)* |
| 臺大學術典藏 |
2018-09-10T08:32:36Z |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia
|
Lin, P.-H. Chiu, C.-F. Lu, Y.-S.; PO-HAN LIN |
| 臺大學術典藏 |
2020-05-25T06:52:00Z |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia
|
Lin P.-H;Chiu C.-F;Yen-Shen Lu; Lin P.-H; Chiu C.-F; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T02:31:42Z |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia
|
PO-HAN LIN; Chiu C.-F.; Lu Y.-S. |
| 嘉南藥理大學 |
2004 |
Cisplatin but not carboplation acts synergistically aith Taxo in killing the oral squamous cellcarcinoma cell line
|
林美惠 |
| 輔英科技大學 |
2012-05-01 |
Cisplatin Disrupts the Latency of Human Herpesvirus 8 and Induces Apoptosis in Primary Effusion Lymphoma Cells
|
Yi-Fen Wang, Yee-Hsuan Chiou, Lin-Yu Wang, Su-Ting Chang, Huey-Wen Shyu, Chang-Yu Chen, Kuan-Hua Lin, and Miao-Chen Chou1 |
| 輔英科技大學 |
2012-05-01 |
Cisplatin Disrupts the Latency of Human Herpesvirus 8 and Induces Apoptosis in Primary Effusion Lymphoma Cells.
|
Yi-Fen Wang, Yee-Hsuan Chiou, Lin-Yu Wang, Su-Ting Chang, Huey-Wen Shyu, Chang-Yu Chen,Kuan-Hua Lin, and Miao-Chen Chou |
| 國立成功大學 |
2013-07 |
Cisplatin downregulates the aryl hydrocarbon receptor nuclear translocator to inhibit MDR1 expression
|
Chang, Wen-Chang; Chen, Ben-Kuen |
| 臺北醫學大學 |
2007 |
Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas
|
李婉若; Hwang TL; Lee WR; Hua SC; Fang JY |
| 元培科技大學 |
2005-03-26 |
Cisplatin Enhanced Chemosensitve Response to P53-Mutated Human Non-Small Cell Lung Cancer Cells with Transfer P161NK4 and P21WAF1,
|
Li, C.H.;Chiu, C.C.;Fuh, T.S.;Chen, W.L.;Wang, Y.H.;Lai, S.H.;Lin, M.Y.;Fang, K |
| 輔英科技大學 |
2016-03-26 |
Cisplatin In Combination With Allyl Isothiocyanate (AITC), A Potential Therapeutic Strategy For Oral Squamous Cell Carcinoma
|
郭順宇 |
| 輔英科技大學 |
2016-03-26 |
Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential therapeutic Strategy for Oral Squamous Cell Carcinoma
|
郭順宇 |
| 國立成功大學 |
2023 |
Cisplatin or Doxorubicin reduces cell viability via the PTPIVA3- JAK2-STAT3 cascade in hepatocellular carcinoma
|
Li, Chao-Jen;Tsai, Hung-Wen;Chen, Yi-Li;Wang, Chun-I;Lin, Yang-Hsiang;Chu, Pei-Ming;Chi, Hsiang-Cheng;Huang, Yi-Ching;Chen, Cheng-Yi; Chen, Cheng-Yi; 陳政義 |
| 國立成功大學 |
2023 |
Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma
|
Li;Chao-Jen;Tsai;Hung-Wen;Chen;Yi-Li;Wang;Chun-;I;Lin;Yang-Hsiang;Chu;Pei-Ming;Chi;Hsiang-Cheng;Huang;Yi-Ching;Chen;Cheng-Yi |
| 國立成功大學 |
2013-01-01 |
Cisplatin Selects for Multidrug-Resistant CD133(+) Cells in Lung Adenocarcinoma by Activating Notch Signaling
|
Liu, Yu-Peng; Yang, Chih-Jen; Huang, Ming-Shyan; Yeh, Chi-Tai; Wu, Alexander T. H.; Lee, Yu-Cheng; Lai, Tsung-Ching; Lee, Chien-Hsin; Hsiao, Ya-Wen; Lu, Jean; Shen, Chia-Ning; Lu, Pei-Jung; Hsiao, Michael |
| 臺北醫學大學 |
2012 |
Cisplatin selects for multidrug-resistant CD133+
|
Liu, YP;Yang, CJ;Hung, MS;Yeh, CT;Wu, AT;Lee, YC;Lai, TC;Lee, CH;Hsiao, YW;Lu |
| 嘉南藥理大學 |
2020 |
Cisplatin sensitivity mediated by NKX2-1 in lung adenocarcinoma is dependent on p53 mutational status via modulating TNFSF10 expression
|
Chen, Ming-Jenn; Chen, Po-Ming; Wang, Lee; Shen, Ching-Ju; Chen, Chi-Yi; Lee, Huei |
| 中山醫學大學 |
2020 |
Cisplatin sensitivity mediated by NKX2-1 in lung adenocarcinoma is dependent on p53 mutational status via modulating TNFSF10 expression
|
Chen, MJ; Chen, PM; Wang, L; Shen, CJ; Chen, CY; Lee, H |
| 國立成功大學 |
2023 |
Cisplatin triggers oxidative stress, apoptosis and pro-inflammatory responses by inhibiting the SIRT1-mediated Nrf2 pathway in chondrocytes
|
Hsieh, P.-L.;Tsai, K.-L.;Chou, W.-C.;Wu, C.-H.;Jou, I.-M.;Tu, Y.-K.;Ma, C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
|
Liu M.-Y.;Chiun Hsu;Lin J.-T.;Yeh K.-H.;Cheng A.-L.; Cheng A.-L.; Yeh K.-H.; Lin J.-T.; Chiun Hsu; Liu M.-Y. |
